Development of a Plaque Infiltrated With Large CD30+ T Cells Over a Silicone-Containing Device in a Patient With History of Sézary Syndrome

Engberg, Anna; Bunick, Christopher G.; Subtil, Antonio; Ko, Christine J.; Girardi, Michael

doi:10.1200/jco.2012.42.9241

Cited by 11 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 A case described by Engberg et al, presented with a unique skin ALCL in a single plague directly over an implanted chemotherapy port (product #0655640, Bard Access Systems) containing silicone and polyurethane. 33 In both of these later cases, patients had previously undergone treatment for lymphoproliferative disorders.…”

Section: Pathogenesismentioning

confidence: 99%

Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Clemens

DeCoster

Fairchild

et al. 2019

Seminars in Plastic Surgery

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging and indolent, but potentially fatal cancer of the immune system that can develop around textured-surface breast implants. The World Health Organization first recognized BIA-ALCL as a unique clinical entity in 2016. To date, over 600 confirmed cases have been reported worldwide. BIA-ALCL most commonly presents with disease confined to the capsule, as a seroma or a mass adjacent to the implant. While BIA-ALCL has a fairly indolent clinical course, with an excellent prognosis in early stage disease, disseminated cancer and death have also been reported. In this review, the authors focus on the early diagnosis and treatment, including reconstructing the breast following BIA-ALCL, and also discuss recently updated National Comprehensive Cancer Network guidelines. They also review the current epidemiology and risk factors associated with BIA-ALCL. Finally, they discuss important medicolegal considerations and the bioethics surrounding the continued use of textured-surface breast implants.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Clemens

DeCoster

Fairchild

et al. 2019

Seminars in Plastic Surgery

View full text Add to dashboard Cite

show abstract

“…Diffuse large B-cell lymphoma has been more frequently reported with various implanted devices [ 48 ]. Similar to BIA-ALCL, case reports of CD30-positive ALK-negative ALCL in patients with dental [ 50 ], gastric lap band [ 51 ], gluteal [ 52 ], and silicone-containing port device implants [ 53 ] have subsequently emerged [ 48 ]. While theories of lymphomagenesis by a proposed mechanism of mechanical friction have been suggested [ 54 ], evidence remains limited in light of the fact that the capsular-implant interface is typically “slick”.…”

Section: Etiology Of Bia-alclmentioning

confidence: 99%

Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research

Deva

Turner

Kadin

et al. 2020

Cancers

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma. Where implant history is known, all confirmed cases to date have occurred in patients with exposure to textured implants. There is a spectrum of disease presentation, with the most common occurring as a seroma with an indolent course. A less common presentation occurs as locally advanced or, rarely, as metastatic disease. Here we review the immunological characteristics of BIA-ALCL and potential triggers leading to its development. BIA-ALCL occurs in an inflammatory microenvironment with significant lymphocyte and plasma cell infiltration and a prominent Th1/Th17 phenotype in advanced disease. Genetic lesions affecting the JAK/STAT signaling pathway are commonly present. Proposed triggers for the development of malignancy include mechanical friction, silicone implant shell particulates, silicone leachables, and bacteria. Of these, the bacterial hypothesis has received significant attention, supported by a plausible biologic model. In this model, bacteria form an adherent biofilm in the favorable environment of the textured implant surface, producing a bacterial load that elicits a chronic inflammatory response. Bacterial antigens, primarily of Gram-negative origin, may trigger innate immunity and induce T-cell proliferation with subsequent malignant transformation in genetically susceptible individuals. Although much remains to be elucidated regarding the multifactorial origins of BIA-ALCL, future research should focus on prevention and treatment strategies, recognizing susceptible populations, and whether decreasing the risk of BIA-ALCL is possible.

show abstract

“…A limitation was that some studies selected CD30-positive cases, which distorted the average number of CD30 positivity. 39,45,46,52,53,56,[64][65][66]69,71 In 28/36 studies 37,38,[44][45][46]48,49,[52][53][54][55][56][57][58][59][60][61][63][64][65][66][67]69,70,[72][73][74][75] a cut-off was missing or very heterogeneous values such as ≥1%, ≥5%, >10, ≥10%, and ≥50% were described. 39,43,47,50,51,62,68,71 The most commonly used thresholds for CD30 expression were ≥1% in cases of C-MF 43,68 and >50% in cases of T-MF.…”

Section: Primary Cutaneous T-cell Lymphomasmentioning

confidence: 99%

“…37,38,51,61,73 There were two case reports of SS with LCT and a CD30 positivity of 50% and 75%, respectively. 58,60 A cut-off of ≥5% and >10% was mentioned in only two studies. 50,51…”

Section: Primary Cutaneous T-cell Lymphomasmentioning

confidence: 99%

A review ofCD30expression in cutaneous neoplasms

Kampa

Mitteldorf

2020

J Cutan Pathol

View full text Add to dashboard Cite

Background: The surface protein CD30 is a therapeutic target of monoclonal antibody therapy. Knowledge of the frequency of CD30 expression and its prognostic relevance is therefore interesting, not only in lymphoproliferative disorders (LPD) but also in solid tumors of the skin. Methods: A review was completed in PubMed for all published reports of CD30 expression in cutaneous lymphomas, mastocytosis, epithelial tumors and sarcomas from 1982 to April 2019. Only accessible articles in English and German were considered. Entities with an expected CD30 expression, such as CD30-positive LPD, were not evaluated. Results: The electronic research identified 1091 articles and a further 34 articles were obtained from manual bibliographic reference. Overall 91 articles were included that examined CD30 expression in various entities of cutaneous neoplasms and matched the inclusion criteria. Conclusion: Apart from cutaneous CD30-positive LPD, the best-studied group for CD30 expression was mycosis fungoides (MF). CD30 positivity was found in 32% of classical (patch and plaque stage) and in 59.4% cases of transformed MF. CD30 was also frequently expressed in cutaneous mastocytosis (96.5%). In solid tumors, some single reports describe CD30 expression by tumor cells, but CD30-reactive lymphocytes were frequently observed in the tumor microenvironment (TME), especially in keratoacanthoma (KA).

show abstract

Development of a Plaque Infiltrated With Large CD30+ T Cells Over a Silicone-Containing Device in a Patient With History of Sézary Syndrome

Cited by 11 publications

References 21 publications

Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research

A review ofCD30expression in cutaneous neoplasms

Contact Info

Product

Resources

About